Table 3.
a Total US-CT agreement scores before and after use of US contrast agent at four escalating doses
| Subject | Pre-contrast Score | Post-contrast Score | % Change |
|---|---|---|---|
| Cohort 1: Dose Level = 0.175 mL/m2 | |||
| 1 | 62 | 67 | 8.1% |
| 2 | 74 | 77 | 4.1% |
| 3 | 68 | 67 | −1.5% |
| Cohort 2: Dose Level = 0.200 mL/m2 | |||
| b4 | 47 | 52 | 10.6% |
| 5 | 67 | 70 | 4.5% |
| b6 | 59 | 62 | 5.1% |
| Cohort 3: Dose Level = 0.275 mL/m2 | |||
| 7 | 68 | 66 | −2.9% |
| 8 | 68 | 64 | −5.9% |
| b9 | 60 | 61 | 1.7% |
| Cohort 4: Dose Level = 0.350 mL/m2 | |||
| 10 | 70 | 75 | 7.1% |
| 11 | 68 | 68 | 0% |
| 12 | 60 | 67 | 11.7% |
Sum of individual parameter US-CT agreement scores for three reviewers for each subject.
The score does not include data for tumor appearance which could not be evaluated due to technical factors.